White Paper

Unifying Cell Therapy Logistics And Manufacturing

supply chain 2 (002)

Cell and gene therapies show promise as effective treatments, but there are some barriers to scaling them beyond the small numbers of patients they reach today. The supply chain and logistics for these advanced therapies are especially critical to ensure the right patient gets the right treatment at the right time. Collaboration is the key to solving challenges such as data management and process variability, as stakeholders work towards a common goal—getting these life-saving treatments to the people who need them.

Here we focus on autologous therapies, such as chimeric antigen receptor T (CAR T) cells. However, many of the challenges also apply to allogeneic therapies, which offer the possibility to reduce cost of goods.

VIEW THE WHITE PAPER!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Drug Discovery Online? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: